660 related articles for article (PubMed ID: 14555528)
1. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells.
Lashinger LM; Zhu K; Williams SA; Shrader M; Dinney CP; McConkey DJ
Cancer Res; 2005 Jun; 65(11):4902-8. PubMed ID: 15930312
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib as a potential treatment for prostate cancer.
Papandreou CN; Logothetis CJ
Cancer Res; 2004 Aug; 64(15):5036-43. PubMed ID: 15289299
[TBL] [Abstract][Full Text] [Related]
4. [Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer].
Tahmatzopoulos A; Gudegast C; Stöckle M; Wullich B; Unteregger G; Zwergel U; Zwergel T
Aktuelle Urol; 2004 Nov; 35(6):491-6. PubMed ID: 15526229
[TBL] [Abstract][Full Text] [Related]
5. The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
Griffith TS; Kemp TJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):175-84. PubMed ID: 12811515
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells.
Goktas S; Baran Y; Ural AU; Yazici S; Aydur E; Basal S; Avcu F; Pekel A; Dirican B; Beyzadeoglu M
Urology; 2010 Apr; 75(4):793-8. PubMed ID: 19800672
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells.
Yu R; Mandlekar S; Ruben S; Ni J; Kong AN
Cancer Res; 2000 May; 60(9):2384-9. PubMed ID: 10811114
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
Ganten TM; Koschny R; Haas TL; Sykora J; Li-Weber M; Herzer K; Walczak H
Hepatology; 2005 Sep; 42(3):588-97. PubMed ID: 16037944
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.
Sartore-Bianchi A; Gasparri F; Galvani A; Nici L; Darnowski JW; Barbone D; Fennell DA; Gaudino G; Porta C; Mutti L
Clin Cancer Res; 2007 Oct; 13(19):5942-51. PubMed ID: 17908991
[TBL] [Abstract][Full Text] [Related]
10. Rapid induction of apoptosis by combination of flavopiridol and tumor necrosis factor (TNF)-alpha or TNF-related apoptosis-inducing ligand in human cancer cell lines.
Kim DM; Koo SY; Jeon K; Kim MH; Lee J; Hong CY; Jeong S
Cancer Res; 2003 Feb; 63(3):621-6. PubMed ID: 12566305
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
Munshi A; McDonnell TJ; Meyn RE
Cancer Chemother Pharmacol; 2002 Jul; 50(1):46-52. PubMed ID: 12111111
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells.
Sridhar S; Ali AA; Liang Y; El Etreby MF; Lewis RW; Kumar MV
Cancer Res; 2001 Oct; 61(19):7179-83. PubMed ID: 11585752
[TBL] [Abstract][Full Text] [Related]
13. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
Thorpe JA; Christian PA; Schwarze SR
Prostate; 2008 Feb; 68(2):200-9. PubMed ID: 18076022
[TBL] [Abstract][Full Text] [Related]
15. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells.
Sun SY; Yue P; Lotan R
Oncogene; 2000 Sep; 19(39):4513-22. PubMed ID: 11002424
[TBL] [Abstract][Full Text] [Related]
16. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
Smith MR; Jin F; Joshi I
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis.
Sanlioglu AD; Koksal IT; Karacay B; Baykara M; Luleci G; Sanlioglu S
Cancer Gene Ther; 2006 Jan; 13(1):21-31. PubMed ID: 16052230
[TBL] [Abstract][Full Text] [Related]
19. Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis.
Kelley TW; Alkan S; Srkalovic G; Hsi ED
Leuk Res; 2004 Aug; 28(8):845-50. PubMed ID: 15203282
[TBL] [Abstract][Full Text] [Related]
20. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
Tafuku S; Matsuda T; Kawakami H; Tomita M; Yagita H; Mori N
Eur J Haematol; 2006 Jan; 76(1):64-74. PubMed ID: 16343273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
